Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer : the OXEL randomized phase II study
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints include the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) was associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.
| Errataetall: |
UpdateIn: Nat Commun. 2024 Mar 27;15(1):2691. - PMID 38538574 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2023) vom: 04. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lynce, Filipa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.04.2024 published: Electronic UpdateIn: Nat Commun. 2024 Mar 27;15(1):2691. - PMID 38538574 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.12.04.23297559 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365966541 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365966541 | ||
| 003 | DE-627 | ||
| 005 | 20240408232158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.04.23297559 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM365966541 | ||
| 035 | |a (NLM)38105958 | ||
| 035 | |a (PII)2023.12.04.23297559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lynce, Filipa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer |b the OXEL randomized phase II study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Nat Commun. 2024 Mar 27;15(1):2691. - PMID 38538574 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints include the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) was associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a TNBC | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a capecitabine | |
| 650 | 4 | |a ctDNA | |
| 650 | 4 | |a nivolumab | |
| 700 | 1 | |a Mainor, Candace |e verfasserin |4 aut | |
| 700 | 1 | |a Donahue, Renee N |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Schlam, Ilana |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongkun |e verfasserin |4 aut | |
| 700 | 1 | |a Toney, Nicole J |e verfasserin |4 aut | |
| 700 | 1 | |a Jochems, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Schlom, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Zeck, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Gallagher, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Nanda, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Deena |e verfasserin |4 aut | |
| 700 | 1 | |a Stringer-Reasor, Erica M |e verfasserin |4 aut | |
| 700 | 1 | |a Denduluri, Neelima |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Chitalia, Ami |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Shruti |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Kaltman, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Khoury, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Gatti-Mays, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Tarantino, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Tolaney, Sara M |e verfasserin |4 aut | |
| 700 | 1 | |a Swain, Sandra M |e verfasserin |4 aut | |
| 700 | 1 | |a Pohlmann, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Parsons, Heather A |e verfasserin |4 aut | |
| 700 | 1 | |a Isaacs, Claudine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2023) vom: 04. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:04 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.04.23297559 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 04 |c 12 | ||